[{"id":"30cdbc8e-86b7-4acf-99c8-3c96ef476491","acronym":"","url":"https://clinicaltrials.gov/study/NCT05996523","created_at":"2023-08-18T15:08:21.065Z","updated_at":"2024-07-02T16:34:36.796Z","phase":"Phase 2","brief_title":"Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer","source_id_and_acronym":"NCT05996523","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PRGN-2009"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-06-10"},{"id":"2365a87d-8e35-400d-9a3b-2c370f444652","acronym":"20-C-0104","url":"https://clinicaltrials.gov/study/NCT04432597","created_at":"2021-01-29T07:20:51.032Z","updated_at":"2024-07-02T16:35:28.048Z","phase":"Phase 1/2","brief_title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","source_id_and_acronym":"NCT04432597 - 20-C-0104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PRGN-2009"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2023-11-27"}]